Almirall's Axert/Almogran approved for adolescents in the USA
Leading Spanish drugmaker Almirall's Axert/Almogran (almotriptan) has been approved in the USA for the acute treatment of migraine headache in adolescent patients (aged 12 to 17 years). Almotriptan obtained an initial approval in the USA in 2001 for the same indication in adults and it is currently being marketed through a licence-out agreement by US health care major Johnson & Johnson's Ortho Janssen Pharmaceuticals in the USA and Canada. The agent is the first triptan to be approved for treatment of migraine in adolescents by the US Food and Drug Administration. Based on completion of the studies that support this approval, a patent extension of six months has been granted in the USA, until November 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze